Last November, the Vatican convened a meeting with leaders of major pharmaceutical and medical technology companies, multilateral organizations, donors, governments, organizations providing or supporting services for children living with HIV, and other key stakeholders in order to discuss how to reduce morbidity and mortality among children living with HIV, particularly by accelerating the development and introduction of priority paediatric formulations of antiretroviral drugs (ARVs). This High-Level Dialogue provided an opportunity for stakeholders to put forward a set of concrete actions they could take to better support the research, development, and introduction spectrum. These commitments, which also build on work within the Global Accelerator for Paediatric Formulations (GAP-f)2 and the Start Free, Stay Free, AIDS Free Framework, form the basis of the Action Plan for Scaling Up Early Diagnosis and Treatment of Children and Adolescents.
The Action plan contains, among others, detailed pledges by pharmaceutical companies and the US Food and Drug Administration (FDA) to accelerate development of child-friendly ARV formulations. PENTA looks forward to the chance to contribute to this initiative.